SuperGen Pulls U.S. Cancer Drug Application  NEW YORK (Reuters) - SuperGen Inc. on Monday said it has  withdrawn an application to market its pancreatic cancer  treatment in the United States due to insufficient data,  sending its shares down 17 percent.